Bone Marrow Failure Syndromes: Clinical Trials

5 trials for Bone Marrow Failure Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 withdrawn. 5 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 2, Recruiting 2, Withdrawn 1
Phase 25Completed 2, Recruiting 2, Withdrawn 1

Follow Bone Marrow Failure Syndromes: new trials by email Literature Review of Bone Marrow Failure Syndromes trials Research Report on Bone Marrow Failure Syndromes

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
Dibotatug (DR-01) - Bone Marrow Failure Syndromes, Aplastic Anemias
Phase 1 / Phase 2RecruitingDren Bio602026-08-142026-11-04
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RIC regimen, GVHD prophylaxis regimen - Severe Sickle Cell Disease, Bone Marrow Failure Syndromes
Phase 1 / Phase 2RecruitingWashington University School of Medicine292017-03-202026-05-29
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
CD45RA-depleted peripheral blood mononuclear cells - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Phase 1 / Phase 2CompletedFederal Research Institute of Pediatric Hematology, Oncology and Immunology302014-08-012016-04-22
Nandrolone Decanoate in the Treatment of Telomeropathies
Nandrolone Decanoate - Aplastic Anemia, Bone Marrow Failure Syndromes
Phase 1 / Phase 2CompletedUniversity of Sao Paulo202014-02-012023-08-31
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Enriched Hematopoetic Stem Cell Infusion - Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies
Phase 1 / Phase 2WithdrawnTalaris Therapeutics Inc.2011-05-012023-03-03

Narrower conditions

Bone Marrow Failure Disorders (5)  ·  Anemia, Aplastic (2)  ·  Anemia, Sickle Cell (2)  ·  Anemia, Diamond-Blackfan (1)  ·  Graft vs Host Disease (1)  ·  Hematologic Diseases (1)  ·  Hemoglobinopathies (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Immune Deficiency Disease (1)  ·  Immune System Diseases (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukocyte Disorders (1)  ·  Metabolic Diseases (1)  ·  Opportunistic Infections (1)  ·  Pancytopenia (1)

Broader conditions

Bone Marrow Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Anemia (4)  ·  Hematologic Diseases (4)  ·  Anemia, Hemolytic (2)  ·  Anemia, Hemolytic, Congenital (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Anemia, Aplastic (1)  ·  Anemia, Hypoplastic, Congenital (1)  ·  Congenital Bone Marrow Failure Syndromes (1)  ·  Cytopenia (1)  ·  Disease Attributes (1)  ·  Hemoglobinopathies (1)  ·  Immune System Diseases (1)

Interventions

Nandrolone Decanoate (1)

Sponsors

Dren Bio (1)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1)  ·  Talaris Therapeutics Inc. (1)  ·  University of Sao Paulo (1)  ·  Washington University School of Medicine (1)

Countries

United States (3)  ·  Brazil (1)  ·  Russia (1)

Top investigators

Ana Beatriz Hortense, MD (1)  ·  Michael Maschan, MD (1)  ·  Rodrigo T Calado, MD, PhD (1)  ·  Shalini Shenoy, MD (1)  ·  Suzanne T Ildstad, MD (1)  ·  Wan-Jen Hong, MD (1)

Results publications

PMID 32813873, PMID 36579443